2024年10月11日 · HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled, auto-injector pen.

2024年10月13日 · Hympavzi is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children aged 12 years of age and older with: hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. The most common side effects of Hympavzi are. itching.

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. For subcutaneous use only.

2024年10月11日 · Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients...

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

Hympavzi is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to TFPI. By attaching to TFPI, Hympavzi prevents its activity and allows blood clotting by the tissue factor pathway in patients with haemophilia A or B.

HYMPAVZI™ (marstacimab) This product information is intended only for residents of the United States. for Consumers: HYMPAVZI™ U.S. Patient Information ; HYMPAVZI™ U.S. Instructions for Use; for Healthcare professionals: HYMPAVZI U.S. Physician Prescribing Information

HYMPAVZI is a prescription medicine used to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

2024年12月27日 · HYMPAVZI is a drug used to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or …

2024年11月6日 · Hympavzi (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital fa...